Shares of MiNK Therapeutics (INKT) surged 73% pre-market after announcing a strategic collaboration with C-Further to advance a PRAME-targeted iNKT cell therapy for pediatric cancers. The partnership focuses on developing a targeted pediatric oncology cell therapy but disclosed no financial terms, milestones, or timelines. The news is highly positive for INKT’s clinical pipeline and drove significant speculative re-rating; expect elevated volatility and the need to reassess valuation based on future clinical progress or deal economics.
Shares of MiNK Therapeutics (INKT) surged 73% pre-market after announcing a strategic collaboration with C-Further to advance a PRAME-targeted iNKT cell therapy for pediatric cancers. The partnership focuses on developing a targeted pediatric oncology cell therapy but disclosed no financial terms, milestones, or timelines. The news is highly positive for INKT’s clinical pipeline and drove significant speculative re-rating; expect elevated volatility and the need to reassess valuation based on future clinical progress or deal economics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
